# EMERALD (EXoPERT extracellular vesicle Raman test)

Source: https://onco.cc/trials/exopert-emerald/  
OnCo record `exopert-emerald` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A US study collecting blood to develop an artificial intelligence test that reads light scattered by tiny vesicles shed from tumours.

## Summary

EMERALD (NCT07186296) is an observational study sponsored by EXoPERT with MCRA. It builds a repository to develop artificial intelligence software that analyses surface-enhanced Raman spectroscopy profiles of plasma extracellular vesicles for early detection of five cancers.

The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 1,400 participants, a start on 9 May 2025 and primary completion expected on 31 August 2026.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-29
- Also known as: EXoPERT EMERALD; EXoPred
- Registry id: NCT07186296
- Phase: observational
- Setting: People with lung, ovarian, breast, pancreatic or colorectal cancer and controls at US sites, building a blood sample repository
- Sponsor: EXoPERT with MCRA
- Enrolled: 1400

## Sources

- ClinicalTrials.gov NCT07186296: https://clinicaltrials.gov/study/NCT07186296

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)

---
JSON: https://onco.cc/api/v1/entities/exopert-emerald.json